The Safety and Immunogenicity of a Potential HIV Vaccine

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

HIV Infections

Interventions

BIOLOGICAL

CN54gp140 mixed with GLA-AF

Each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF

Trial Locations (1)

NIHR/Wellcome Trust Imperial Clinical Research Facility, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London

All Listed Sponsors

collaborator

Wellcome Trust

OTHER

collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

Imperial College London

OTHER

NCT01966900 - The Safety and Immunogenicity of a Potential HIV Vaccine | Biotech Hunter | Biotech Hunter